Comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 vs 3q26q28 Deletion Syndrome C6010434
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Exogenous Maternal Derived Androgen and 3q26q28 Deletion Syndrome for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
A condition caused when a pregnant person takes hormone medications containing androgens, affecting fetal development. The fetus has XX chromosomes. Stopping the offending agent is key, with specialist care for affected infants.
3q26q28 Deletion Syndrome C6010434
A genetic condition involving deletion of part of chromosome 3q26q28, typically causing developmental delays, growth issues, and multiple congenital differences.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Variable
3q26q28 Deletion Syndrome C6010434
Variable
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
severe
3q26q28 Deletion Syndrome C6010434
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
Chronic
3q26q28 Deletion Syndrome C6010434
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
No
3q26q28 Deletion Syndrome C6010434
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
reproductive
3q26q28 Deletion Syndrome C6010434
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
endocrine
3q26q28 Deletion Syndrome C6010434
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-exogenous-maternal-derived-androgen-C5679874 and 3q26q28-deletion-syndrome-C6010434 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3q26q28 Deletion Syndrome C6010434 | Discriminating power |
|---|---|---|---|
| Genital development | XX fetus may show androgen-related atypical genital development; extent varies. | Genital findings are not established as characteristic from the supplied description. | Moderate |
| Development and growth | Broader developmental delay is not established by the source description. | Typically associated with developmental delay, growth issues, and congenital differences. | High |
| Exposure history | Linked to androgen-containing medication taken during pregnancy. | Caused by deletion of chromosome region 3q26q28, not medication exposure. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 when
Documented androgen medication during pregnancy
The source specifically links fetal XX development to exogenous maternal androgen.
High
XX karyotype with atypical genital findings
Supports consideration, but other causes must still be excluded clinically.
Moderate
Need to stop an implicated exposure
Stopping the offending agent is described as key, alongside specialist infant care.
Moderate
Choose 3q26q28 Deletion Syndrome C6010434 when
Multiple congenital differences with delay
Fits the described pattern better than isolated androgen exposure.
Moderate
Suspected chromosomal deletion
Genetic testing is needed to confirm a 3q26q28 deletion.
High
No relevant androgen exposure history
Makes the exposure-related diagnosis less likely, without proving the deletion.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874 | 3q26q28 Deletion Syndrome C6010434 | Interpretation |
|---|---|---|---|
| Karyotype | XX chromosomes are part of the named condition. | May be normal unless the deletion is visible; not definitive alone. | XX status does not distinguish all causes of atypical development. |
| Chromosomal microarray | No deletion is implied by the supplied description. | Can detect copy-number loss involving 3q26q28 when present. | Confirmation should be interpreted by a genetics clinician. |
| Medication and endocrine review | History may identify androgen-containing pregnancy medication. | No specific endocrine abnormality is established here. | Exposure history supports, but does not alone prove, causation. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Exogenous Maternal Derived Androgen C5679874
- Outcome
- Course may be chronic, but individual outcome is not established.
- Factors
- Timing and nature of exposure and clinical findings may matter.
3q26q28 Deletion Syndrome C6010434
- Outcome
- Often chronic, with variable developmental and congenital effects.
- Factors
- Deletion extent and associated anomalies may influence needs.
Time frame: From prenatal or congenital recognition into longer-term follow-up.
Prognosis should be individualized; comparative outcomes are not established.
Complications comparison
| Complication | Presentation |
|---|---|
| Congenital differences | Primarily concerns fetal sex development; other anomalies are not established. Multiple congenital differences are described as typical. Individual features and severity vary and need specialist assessment. |
| Growth or developmental concerns | Not established from the available description. Developmental delay and growth issues are typical associations. Early developmental surveillance is appropriate when suspected. |
| Ongoing care needs | Specialist care for affected infants is advised. Chronic multidisciplinary support may be needed. Exact complications and outcomes are not quantified here. |
Patient education highlights
- HighDifferent causes
One condition is linked to pregnancy androgen exposure; the other is a chromosomal deletion.
- HighSpecialist evaluation
Diagnosis, counseling, and care plans should be made by qualified clinicians.
- MediumAvoid unsupported numbers
Prevalence, exact test cutoffs, mortality, and treatment doses are not established here.